Novel Trojan Horse Therapy Specifically Degrades Tau Protein
Alzheimer's disease (AD) belongs to a group of neurodegenerative diseases that severely affect brain thinking, cognitive and memory functions, and impose far-reaching and serious burdens on families and society. It is well known that there are two misfolded and aggregated proteins in the neurons of the brain of AD patients: β-amyloid (Aβ) and Tau proteins. These two protein aggregates are diagnostic markers for AD patients and are also considered to be key drivers of AD development, thus targeting and removing these proteins is an important strategy in the development of AD therapies.
In this article, Creative Biolabs introduces novel therapies that are specific for removing disease-associated Tau protein aggregates and blocking aggregate formation, exploring the mysteries of precision therapy for AD.
We are a global provider of neuroscience research services. Our customized services cover all aspects of your customized needs in the field of neuroscience. Our services and products will provide you with cutting-edge platforms that can exponentially accelerate the process of neuroscience research. The table below shows the related services we provide.
Our Services | Descriptions |
AD In Vitro Assay | Creative Biolabs has established an advanced platform for Aβ and tau detection. We are committed to providing professional AD in vitro testing services to customers around the world. |
AD In Vitro Disease Models | As a leading global CRO company focusing on neuroscience research, Creative Biolabs has an advanced technology platform providing various kinds of AD invitro model services to help accelerate AD studies. |
Alzheimer's Disease (AD) Drug Discovery Service | The development or reuse of drugs that can target different aspects of the pathogenesis of AD has become a hope for the treatment of AD. Creative Biolabs can apply our considerable experience with AD solutions to develop the necessary analytics specific to your neuroscience research project. |
Targeted Clearance of Protein Aggregation: Explorations and Bottlenecks
Antibody therapies for Aβ, which form in the spaces between brain cells, have shown initial success. two monoclonal antibodies for early Alzheimer's disease were approved by the FDA in 2023 and July 2024: Lecanemab and Donanemab, which target Aβ. Monoclonal antibodies are able to reduce amyloid β plaques in the brain, thereby slowing cognitive decline in patients by 25 to 35 percent. Monoclonal antibodies reduce amyloid β plaques in the brain, which in turn slows cognitive decline by 25 to 35 percent. Although drugs cannot cure AD, they can slow the disease process and improve quality of life.
Targeted removal of Tau protein aggregates is challenging. One of the hallmark pathologies of AD is neurofibrillary tangles composed of highly phosphorylated Tau protein (P-Tau), which are mainly formed inside nerve cells and are difficult for therapeutic antibodies to access. Other strategies for targeting intracellular Tau, such as antisense oligonucleotides (ASOs), have been effective in reducing intracellular Tau in early clinical trials, but they act on all Tau proteins in the brain, removing healthy Tau. How to specifically remove phosphorylated Tau aggregates is key.
Creative Biolabs is a key supplier of neuroscience research tools worldwide, specializing in the research, development and production of high quality neural cells, antibody products. For Tau protein related research, we offer a range of research tools, including but not limited to the following:
Cat. No | Product Name | Product Category | Applications |
NRP-0322-P2173 | Human Tau Aggregation Kit | Kits | Alzheimer's disease |
NRP-0322-P2174 | Total Tau Cellular Kit | Kits | Alzheimer's disease |
NRZP-0722-ZP220 | Human Tau proteins ELISA kit | Kits | ELISA |
NCL2110P219 | Green Fluorescent Tau SH-SY5Y cell Line | Cells | Cell Culture |
NCL2110P22 | Tau-tGFP (0N4R isoform) Overexpressed SH-SY5Y Cell Line | Cells | Cell Culture |
NRZP-0822-ZP187 | DEPTAC [Tau Dephosphorylation] | Cell Assay Reagents | Alzheimer's disease |
NAB-0720-Z3484 | Rat Anti-14-3-3 Tau Monoclonal Antibody (CBP935) | Antibody | WB |
NAB-0720-Z4212 | NeuroMab™ Rabbit Anti-Tau (CBP1082) | Antibody | IP; ICC; IF; WB; IHC-P; IHC-Fr; DB |
NAB-0720-Z4237 | Mouse Anti-Tau Monoclonal Antibody (CBP1105) | Antibody | IHC-P; WB |
NAB-0720-Z4297 | NeuroMab™ Mouse Anti-Tau (CBP1135) | Antibody | WB; ELISA |
NAB2007FY658 | NeuroMab™ Mouse Anti-Tau Monoclonal Antibody (CBP2019) | Antibody | WB |
Novel Trojan Horse Therapy: Specific Clearance of Tau Protein Tangles
Recently, researchers published articles developing two new therapies for AD that utilize the TRIM21 protein to precisely remove Tau protein aggregates.
- TRIM21 as a tool for capturing Tau aggregates
The new technologies published targeting Tau aggregates all utilize the TRIM21 protein, which was initially shown to play an important role in the immune system's response to viral invasion. When a virus invades the body, antibodies produced by the body outside the cell bind to the virus. When these antibody-bound viruses enter the cell, they are recognized and tagged as trash by TRIM21, which is then destroyed by the intracellular proteasome.
Utilizing the unique advantages of the TRIM21 protein, it can be used to disrupt Tau protein aggregates associated with AD.
By replacing the virus-binding antibody with a Tau-binding antibody, TRIM21 is redirected so that Tau aggregates are destroyed by the proteasome. It is worth noting that the 'RING' structural domain of the TRIM21 protein is only activated when two or more TRIM21 proteins are aggregated together. Thus, TRIM21 proteins are activated and labeled for destruction only when they bind to neighboring aggregated Tau proteins. Based on this, Trojan horse therapy was proposed and validated.
- Two trojan horse therapies targeting Tau proteins
Novel RING-nanobody therapeutics fuse a nano-antibody that binds to Tau protein with a TRIM21-RING, which is activated when the Tau protein forms aggregates, thereby inducing degradation of the aggregates.
Novel RING-Bait therapy, connecting TRIM21-RING with Tau protein itself. The RING-conjugated Tau protein acts as a bait, which is incorporated into the protein aggregates, and the RING of TRIM21 is then incorporated as well. Once multiple “RING-Bait” are added to the aggregate, they are activated, leading to the disruption of the entire aggregate.
The researchers believe that Tau protein aggregates are hidden inside brain cells and are difficult to degrade. The new TRIM21-based therapeutic can be delivered directly inside the cell, thus degrading Tau aggregates without affecting healthy Tau proteins.
Tackling AD and Other Neurological Diseases
The proposal of Trojan horse therapy has provided a new direction and hope for therapeutic research of neurological diseases such as AD. Efficient removal of phosphorylated Tau is the key to Alzheimer's disease therapeutic strategies, and researchers will need to continue to explore this area in order to comprehensively address neurological diseases such as AD.
As people have a new understanding of the pathogenesis and progression of AD, the development or reuse of drugs that can target different aspects of the pathogenesis of AD has become a hope for the treatment of AD. Creative Biolabs can apply our considerable experience with AD solutions to develop the necessary analytics specific to your neuroscience research project. Please feel free to contact us for more details.
Related Scientific Resources
- NeuroMab™ Anti-EPHB2 Antibody(NRP-0422-P1220) (Cat#: NRP-0422-P1220)
- NeuroMab™ Anti-SEZ6 Antibody(NRP-0422-P515) (Cat#: NRP-0422-P515)
- NeuroMab™ Anti-Alpha Synuclein Antibody(NRP-0422-P614) (Cat#: NRP-0422-P614)
- NeuroMab™ Mouse Anti-SHANK3 Monoclonal Antibody (CBP929) (Cat#: NAB-0720-Z3477)
- NeuroMab™ Anti-GD2 Antibody(NRZP-1222-ZP767) (Cat#: NRZP-1222-ZP767)
- NeuroMab™ Rabbit Anti-Alpha-synuclein (CBP1631) (Cat#: NAB-08-PZ079)
- NeuroMab™ Anti-FGFR1 Antibody(NRP-0422-P1244) (Cat#: NRP-0422-P1244)
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P2275) (Cat#: NRP-0422-P2275)
- NeuroMab™ Anti-ApoC3 BBB Shuttle Antibody(NRZP-1022-ZP3505) (Cat#: NRZP-1022-ZP3505)
- NeuroMab™ Anti-Amyloid Beta 1-15 Antibody(NRP-0422-P867) (Cat#: NRP-0422-P867)
- Human Blood Brain Barrier Model (Cat#: NCL-2103-P187)
- Human Hippocampal Neuron Cells HPPNCs (Cat#: NCL2110P106)
- Mouse Glioma Cell Line GL-261-Luc (Cat#: NCL-2108P06)
- Mouse Microglia from C57BL/6 (Cat#: NCL-21P6-082)
- Green Fluorescent BACE1 Cell Lines (Cat#: NCL2110P214)
- Human Brain Vascular Pericytes (Cat#: NCL-21P6-015)
- iNeu™ Retinal Pigment Epithelial Cells (RPE) (Cat#: NRZP-0323-ZP92)
- Human Astrocytes, Immortalized (Cat#: NCL-2105-P182-AM)
- Rat Muller Cell (Cat#: NCL2110P040)
- Mouse Glioma Cell Line GL261-GFP (Cat#: NCL-2108P04)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Dextran, Cy5 Labeled, 2000 kDa (Cat#: NRZP-0722-ZP22)
- PRV-CAG-EGFP (Cat#: NTA-2011-ZP14)
- AAV-mDLX-CRE-tdTomato (Cat#: NRZP-0622-ZP721)
- pAAV-EF1a-DIO-EGFP-WPRE (Cat#: NTA-2012AD-P285)
- AAV2/2Retro-CAG-DIO-EGFP-2A-TetTox-pA [Neural Tracing] (Cat#: NTA-2012-ZP303)
- rAAV-E-SARE-Cre-ERT2-PEST-WPRE-hGH polyA (Cat#: NTA-2010-TT342)
- Dextran, NHS Activated, 40 kDa (Cat#: NRZP-0722-ZP124)
- Dextran-CYanine5.5 (Cat#: NTA-2011-ZP118)
- rAAV-CAG-DIO-G-Flamp1 (Cat#: NRZP-0722-ZP719)
- pAAV-syn-jGCaMP8s-WPRE (Cat#: NTA-2106-P063)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- Rat Parkinson disease (autosomal recessive, juvenile) 2, parkin (Park2) (NM_020093) ORF clone/lentiviral particle, Myc-DDK Tagged (Cat#: NEP-0621-R0041)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP501)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein (Cat#: NRZP-0423-ZP506)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP509)